Loading…
Lobbying Spend
—
Filings
10
Firms Hired
1
Active Period
2025–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
2026 · third_quarter · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1843
Affordable Prescriptions for Patients Act
2026 · third_quarter · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Client expense: — · Firm income: $60,000
Matched citations: S.1041
Preserve Access to Affordable Generics and Biosimilars Act
2026 · third_quarter · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Client expense: — · Firm income: $60,000
Matched citations: S.1096
Increasing Transparency in Generic Drug Applications Act
2026 · third_quarter · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Client expense: — · Firm income: $60,000
Matched citations: S.1302
Prescription Pricing for the People Act of 2025
2026 · third_quarter · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Client expense: — · Firm income: $60,000
Matched citations: S.527
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
2026 · second_quarter · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1843
Affordable Prescriptions for Patients Act
2026 · second_quarter · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Client expense: — · Firm income: $60,000
Matched citations: S.1041
Preserve Access to Affordable Generics and Biosimilars Act
2026 · second_quarter · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Client expense: — · Firm income: $60,000
Matched citations: S.1096
Increasing Transparency in Generic Drug Applications Act
2026 · second_quarter · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Client expense: — · Firm income: $60,000
Matched citations: S.1302
Prescription Pricing for the People Act of 2025
2026 · second_quarter · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Client expense: — · Firm income: $60,000
Matched citations: S.527
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
2026 · first_quarter · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1843
Affordable Prescriptions for Patients Act
2026 · first_quarter · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Client expense: — · Firm income: $60,000
Matched citations: S.1041
Preserve Access to Affordable Generics and Biosimilars Act
2026 · first_quarter · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Client expense: — · Firm income: $60,000
Matched citations: S.1096
Increasing Transparency in Generic Drug Applications Act
2026 · first_quarter · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Client expense: — · Firm income: $60,000
Matched citations: S.1302
Prescription Pricing for the People Act of 2025
2026 · first_quarter · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Client expense: — · Firm income: $60,000
Matched citations: S.527
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
2025 · fourth_quarter · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1843
Affordable Prescriptions for Patients Act
2025 · fourth_quarter · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Client expense: — · Firm income: $60,000
Matched citations: S.1041
Preserve Access to Affordable Generics and Biosimilars Act
2025 · fourth_quarter · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Client expense: — · Firm income: $60,000
Matched citations: S.1096
Increasing Transparency in Generic Drug Applications Act
2025 · fourth_quarter · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Client expense: — · Firm income: $60,000
Matched citations: S.1302
Prescription Pricing for the People Act of 2025
2025 · fourth_quarter · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Client expense: — · Firm income: $60,000
Matched citations: S.527
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
2025 · fourth_quarter · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1843
Affordable Prescriptions for Patients Act
2025 · fourth_quarter · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Client expense: — · Firm income: $60,000
Matched citations: S.1041
Preserve Access to Affordable Generics and Biosimilars Act
2025 · fourth_quarter · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Client expense: — · Firm income: $60,000
Matched citations: S.1096
Increasing Transparency in Generic Drug Applications Act
2025 · fourth_quarter · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Client expense: — · Firm income: $60,000
Matched citations: S.1302
Prescription Pricing for the People Act of 2025
2025 · fourth_quarter · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Client expense: — · Firm income: $60,000
Matched citations: S.527
Source: Senate LDA